Ceftriaxone (Rocephin)

Emergency & Prehospital

• Suspected sepsis or septic shock: the empiric first dose, when a community-acquired source is likely. Pair it with other agents by source and risk. Possible septic shock, or probable or definite sepsis: give it immediately, ideally within 1 hr. Possible sepsis without shock: within 3 hr, if concern persists after rapid assessment. Children (SSC pediatric 2026): suspected septic shock gets it as soon as possible, ideally within 1 hr of recognition. Probable sepsis without shock: after rapid evaluation, ideally within 3 hr
• Suspected bacterial meningitis or meningococcal disease: the first-line empiric agent, and in US practice it goes in with vancomycin. Meningococcal disease, strongly suspected: give IV or IM as soon as possible outside the hospital, unless that delays transfer. Bacterial meningitis, strongly suspected: give it outside the hospital only if transfer will be significantly delayed. Never delay transport to give it. See Field & Transport for scope and allergy limits.

ED / ICU / Transport

• Community-acquired pneumonia (inpatient): a beta-lactam backbone with a macrolide. In nonsevere CAP, a respiratory fluoroquinolone alone is the alternative to that pair. In severe CAP, the partner is a macrolide or a respiratory fluoroquinolone.
• Pyelonephritis and complicated urinary tract infection: when local susceptibility supports it
• Intra-abdominal infection, including spontaneous bacterial peritonitis: add metronidazole for anaerobic coverage in secondary peritonitis. In SBP, IV albumin follows cirrhosis guidance.
• Cirrhosis with upper GI bleeding: short-course infection prophylaxis (off-label)
• Bacteremia, bone and joint, and skin and soft-tissue infections: susceptible organisms
• Lyme carditis needing admission: IV until clinical improvement, then oral to complete the course (off-label)
• Lyme meningitis: IV ceftriaxone or oral doxycycline, equally recommended options (off-label)

Other Uses

• Gonorrhea: single IM dose for uncomplicated infection; IV for disseminated infection; part of pelvic inflammatory disease (PID) and acute epididymitis regimens
• Meningococcal chemoprophylaxis: close contacts, including clinicians exposed to respiratory secretions during airway management
• Acute otitis media (pediatric): single IM dose (label), or once daily for 1 or 3 days (AAP otitis media guideline), when oral therapy is not possible; a 3-day course after first-line treatment fails
• Surgical prophylaxis: single preoperative dose for selected contaminated or potentially contaminated procedures (labeled)

Doses vary by protocol; follow local protocols and medical direction.

Available Forms

• Powder vials: 250 mg, 500 mg, 1 g and 2 g single-dose vials for IV or IM use; contains about 3.6 mEq sodium per gram
• IV reconstitution: 1 g with 9.6 mL (2 g with 19.2 mL) gives 100 mg/mL; dilute further to 10–40 mg/mL for infusion
• IM reconstitution: 250 mg/mL or 350 mg/mL with sterile water or 1% lidocaine without epinephrine (e.g. 1 g + 2.1 mL = 350 mg/mL)
• Premixed frozen bags: 1 g or 2 g in 50 mL iso-osmotic dextrose (Galaxy); thaw, do not refreeze

Adult Dosing

Pediatric Dosing

Check the math with weight-based dosing.

Preparation & Administration

• Diluent: sterile water, 0.9% sodium chloride or D5W. Never lactated Ringer's, Ringer's or Hartmann's solution, or any calcium-containing fluid
• IV infusion: the labeled rate is over 30 min at 10–40 mg/mL, and over 60 min in neonates. An IV push over a few minutes is off-label. It is still widely used under institutional policy, but outcome data in critically ill patients are mixed.
• IM: deep into a large muscle, and aspirate before you inject. A lidocaine-containing solution is for IM use only.
• Line and flush: never run it with calcium-containing fluids in the same line or Y-site. In patients older than 28 days, give the two in sequence, with a thorough flush of a compatible fluid between them.
• Light and color: protect the powder from light. A reconstituted solution that runs light yellow to amber is normal.

Contraindications

• Known hypersensitivity to ceftriaxone, any cephalosporin or an excipient
• Premature neonates up to a postmenstrual age of 41 weeks
• Hyperbilirubinemic neonates (bilirubin displacement and encephalopathy)
• Neonates 28 days or younger who need, or are expected to need, IV calcium-containing solutions, including parenteral nutrition
• IV injection of a solution reconstituted with lidocaine; lidocaine allergy when lidocaine is the IM diluent

Precautions

• Penicillin allergy: cross-reactivity with third-generation cephalosporins is under 1%. Ceftriaxone can be given without testing for a non-anaphylactic penicillin allergy. Per the 2022 AAAAI/ACAAI practice parameter, it can also follow penicillin anaphylaxis, because its side chain differs from the penicillins. Avoid it after a reaction to ceftriaxone or to a cephalosporin with a similar side chain (e.g. cefotaxime, cefepime), or after SJS/TEN to any beta-lactam, unless an allergist advises otherwise.
• Prior ceftriaxone exposure, cardiac disease, older age: these were common features of the deaths and arrests in the 2024–2025 US investigation, which had no comparison group. Product testing found no defect and no new safety issue. Be ready to treat anaphylaxis, including after outpatient doses.
• Severe renal impairment: the risk of encephalopathy, myoclonus and seizures is higher
• Prior ceftriaxone-associated hemolytic anemia: do not re-expose
• Biliary stasis, TPN, prolonged high doses or children: these carry a risk of pseudolithiasis, pancreatitis and urolithiasis. Keep the patient hydrated.
• Vitamin K deficiency (malnutrition, chronic liver disease) or warfarin: PT can rise

Common

• Eosinophilia (about 6%), thrombocytosis (about 5%), leukopenia (about 2%)
• Diarrhea or loose stools (about 3%)
• Raised AST or ALT (about 3%)
• Rash (about 2%)
• Injection-site pain, induration and tenderness (about 1% overall); phlebitis after IV (under 1%)
• IM injection: warmth, tightness or induration in 5% at 250 mg/mL and 17% at 350 mg/mL (small samples). Using 1% lidocaine as the IM diluent takes the sting out

Serious / Life-Threatening

Overdose & Toxicity Management

• Presentation: overdose has happened in severe renal impairment, with encephalopathy, myoclonus, seizures and non-convulsive status epilepticus.
• Management: stop the drug; supportive care; treat seizures with a benzodiazepine per protocol
• No antidote: there is none. Hemodialysis and peritoneal dialysis do not lower levels.

Clinically Significant Interactions

IV Compatibility

• Compatible diluents: sterile water, 0.9% sodium chloride, D5W, D10W
• Incompatible: any calcium-containing solution; vancomycin, aminoglycosides and fluconazole in admixture; D5W with 0.9% or 0.45% sodium chloride under refrigeration
• Sequential antibiotics: when vancomycin follows ceftriaxone, flush the line well between them; do not piggyback ceftriaxone into other antimicrobial solutions
• Verify with an institutional compatibility resource.

• Pediatrics: biliary pseudolithiasis and urinary precipitates are most likely in children, so check the Pediatric Dosing table. Of the cephalosporins, ceftriaxone is the only one CDC recommends for gonorrhea in children.
• Neonates: it is contraindicated in premature neonates (up to 41 weeks postmenstrual age), in hyperbilirubinemic neonates, and in neonates 28 days or younger who need IV calcium. When it is used, give it IV over 60 min. Otherwise, choose an alternative per neonatal or infectious diseases guidance. Guidelines differ. For neonatal gonococcal infection, CDC 2021 advises giving ceftriaxone cautiously to hyperbilirubinemic neonates, especially preterm ones, instead of withholding it. It also lists cefotaxime 100 mg/kg IV or IM once (where available) for when IV calcium is needed.
• Pregnancy: it crosses the placenta. Animal studies at high doses showed no harm, but controlled human data are lacking. It is the recommended regimen for gonorrhea. For meningococcal chemoprophylaxis, rifampin and ciprofloxacin are not recommended in pregnancy (CDC surveillance manual). Do not withhold it for a serious infection.
• Lactation: low concentrations pass into human milk. The label advises caution.
• Older Adults: the pharmacokinetics change little. No adjustment is needed up to 2 g/day, unless severe renal and hepatic impairment coexist. Neurotoxicity is more likely with renal impairment.
• Renal Impairment: no routine adjustment, because it clears through both the kidneys and the bile. Hemodialysis and peritoneal dialysis don't remove it, so there is no supplemental dose after dialysis. The label also calls for appropriate dose adjustment in severe renal impairment because of neurotoxicity. Watch mental status closely.
• Hepatic Impairment: no adjustment on its own. With severe hepatic plus significant renal disease, the max is 2 g/day, with close monitoring.
• Obesity / Dosing Weight: adult doses are fixed, not weight-based. CDC uses 1 g for gonorrhea at 150 kg or more.
• Penicillin Allergy: see Contraindications & Precautions. For cephalosporin allergy in gonorrhea, CDC lists gentamicin 240 mg IM plus azithromycin 2 g PO. In December 2025, the FDA approved two oral agents for uncomplicated urogenital gonorrhea in patients 12 and older at or above a minimum weight: zoliflodacin (77 lb) and gepotidacin (99 lb). Gepotidacin is for patients with few or no other treatment choices. CDC 2021 guidance may not reflect these approvals yet, so consult infectious diseases or the health department.

• Scope: paramedic and above, and critical-care transport, only where the agency carries it and the medical director has approved it. Not on the AEMT IV list. Meningococcal disease, strongly suspected: give IV or IM ceftriaxone outside the hospital as soon as possible, unless it would delay transfer. Bacterial meningitis, strongly suspected: give it outside the hospital only if transfer will be significantly delayed. Never delay transport to give it. Do not give it with a severe ceftriaxone or penicillin allergy. NICE NG240 1.2.6 names ceftriaxone and benzylpenicillin. For in-hospital use, see Precautions. For sepsis, SSC 2026 suggests ambulance or flight antibiotics (conditional, very low certainty), but only for adults with probable or definite sepsis and hypotension (septic shock), when in-hospital evaluation is expected to take more than 60 min. That applies only where a structured prehospital sepsis screening process is in place. Varies by state and agency protocol.
• Storage & Stability: powder at 20–25°C (68–77°F), protected from light. Reconstituted IV solution (10–40 mg/mL in water, saline or D5W): 2 days at room temperature; IM solution (250–350 mg/mL): 24 hr at room temperature. Thawed premixed bags: 48 hr at room temperature or 21 days refrigerated.
• Carried Concentration: IV is 100 mg/mL after reconstitution, and IM is 350 mg/mL with lidocaine. Label every syringe with its route and diluent, so a lidocaine syringe never goes IV.
• Infusions in Transport: trace every line; if lactated Ringer's is running, use a separate line or stop and flush thoroughly before and after the dose.
• Exposure and Precautions: use droplet precautions for suspected meningitis. Clinicians who managed the airway or were exposed to respiratory secretions need chemoprophylaxis as soon as possible. More than 14 days after onset, it is of little value.
• Handoff Essentials: dose, route, time given (next dose due in 12–24 hr), whether cultures were drawn first, allergy history, any reaction, and which line was used.

Mechanism of Action

• It binds penicillin-binding proteins and blocks cell-wall cross-linking, so dividing bacteria lyse. That is bactericidal.
• Some beta-lactamases leave it active. Others hydrolyze it, extended-spectrum beta-lactamases (ESBLs) among them.
• Time-dependent killing: efficacy tracks how long free drug stays above the MIC. The long half-life allows once-daily dosing.
• It gets into the CSF through inflamed meninges, at bactericidal levels.

Pharmacokinetics

• Half-life: 5.8–8.7 hr in healthy adults; about 4.5 hr in children with meningitis; 11–16 hr in renal impairment and on hemodialysis
• Metabolism: minimal. The biliary fraction shows up in feces as microbiologically inactive compounds.
• Elimination: 33–67% unchanged in urine, the rest in bile and feces
• Protein binding: 85–95%, and concentration-dependent. It displaces bilirubin from albumin.

Generic Name

Ceftriaxone sodium

Brand Names

Rocephin (discontinued in the US); generic vials and premixed bags from multiple manufacturers

Pharmacologic Class

Third-generation cephalosporin; beta-lactam

Therapeutic Class

Parenteral antibacterial

Controlled Substance

Not controlled

ISMP High-Alert

No

Look-Alike / Sound-Alike

cefTRIAXone / ceFAZolin / cefoTEtan / cefOXitin / cefTAZidime (ISMP confused-names pairs)